Trial Profile
A 12-Month, Randomized, Active-controlled, Open-label Study of the Efficacy and Safety of Oral Testosterone Undecanoate in Hypogonadal Men (RE-TUne)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Jul 2023
Price :
$35
*
At a glance
- Drugs Testosterone undecanoate (Primary) ; Testosterone
- Indications Hypogonadism
- Focus Registrational; Therapeutic Use
- Acronyms RE-TUne
- Sponsors Marius Pharmaceuticals; SOV Therapeutics
- 23 Mar 2021 Results presented at the 103rd Annual Meeting of the Endocrine Society.
- 05 Jan 2021 According to a Marius Pharmaceuticals media release, results will be published in leading medical journals and presented at national conferences during 2021.
- 30 Jun 2020 Status changed from recruiting to completed.